Get the Stockscreener App
1.315
2.96%
-0.035
Pmv Pharmaceuticals Inc stock is traded at $1.315, with a volume of 154.32K.
It is down -2.96% in the last 24 hours and down -16.03% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
See More
Previous Close:
$1.35
Open:
$1.35
24h Volume:
154.32K
Relative Volume:
0.13
Market Cap:
$69.97M
Revenue:
-
Net Income/Loss:
$-51.47M
P/E Ratio:
-1.315
EPS:
-1
Net Cash Flow:
$-47.50M
1W Performance:
-6.43%
1M Performance:
-16.03%
6M Performance:
+44.59%
1Y Performance:
-17.61%
1-Day Range:
$1.30
$1.36
1-Week Range:
$1.30
$1.44
52-Week Range:
$0.81
$1.84
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.315 | 71.84M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.04 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.48 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.84 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.72 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.36 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison - Defense World
Why PMV Pharmaceuticals Inc. stock is a must watch in 2025Trade Risk Summary & Safe Entry Zone Identification - newser.com
Why PMV Pharmaceuticals Inc. stock appeals to analysts2025 Retail Activity & Precise Swing Trade Entry Alerts - newser.com
Contrasting PMV Pharmaceuticals (NASDAQ:PMVP) & Kiora Pharmaceuticals (NASDAQ:KPRX) - Defense World
Is PMV Pharmaceuticals Inc. stock poised for growth2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
How rising interest rates impact PMV Pharmaceuticals Inc. stockPortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Will PMV Pharmaceuticals Inc. stock outperform Dow Jones index2025 Price Targets & Real-Time Price Movement Reports - newser.com
Will PMV Pharmaceuticals Inc. stock benefit from commodity pricesCEO Change & Growth Oriented Trading Recommendations - newser.com
Is PMV Pharmaceuticals Inc. stock safe for conservative investorsJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
Is PMV Pharmaceuticals Inc. building a consolidation base2025 Volatility Report & Stock Portfolio Risk Control - newser.com
Top Penny Stocks To Watch In November 2025 - simplywall.st
Can PMV Pharmaceuticals Inc. stock deliver surprise earnings beat2025 Fundamental Recap & Safe Investment Capital Preservation Plans - newser.com
HC Wainwright Issues Positive Outlook for PMVP Earnings - Defense World
Published on: 2025-11-16 01:59:30 - newser.com
Real time social sentiment graph for PMV Pharmaceuticals Inc.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Sio Capital Management, LLC Reduces Stake in PMV Pharmaceuticals Inc - GuruFocus
PMV Pharmaceuticals Places Big Bet On Cancer Drug Rezatapopt - Finimize
PMV Pharmaceuticals Reports Increased Quarterly Loss - TipRanks
Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential - TipRanks
PMV Pharma (PMVP) Plans NDA Submission for Ovarian Cancer Treatm - GuruFocus
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights - The Manila Times
PMV Pharma Q3 net loss widens to $21.1 mln - MarketScreener
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] PMV Pharmaceuticals, Inc. Quarterly Earnings Report | PMVP SEC FilingForm 10-Q - Stock Titan
[8-K] PMV Pharmaceuticals, Inc. Reports Material Event | PMVP SEC FilingForm 8-K - Stock Titan
PMV Pharma (NASDAQ: PMVP) posts 46% ORR in ovarian cancer; median 8.0-month response - Stock Titan
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):